Published in Blood Weekly, February 10th, 2000
R. Haq and colleagues designed a study to evaluate the efficacy and toxicity of dose intensifying DHAP (dexamethasone, cytarabine and cisplatin) salvage chemotherapy by adding miloxantrone with granulocyte-macrophage colony-stimulating factor (GM-GSF) support in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) ("Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma," Leukemia & Lymphoma,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.